|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Massari F, Ciccarese C, Santoni M,
Brunelli M, Piva F, Modena A, Bimbatti D, Fantinel E, Santini D,
Cheng L, et al: Metabolic alterations in renal cell carcinoma.
Cancer Treat Rev. 41:767–776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oh-I S, Shimizu H, Satoh T, Okada S,
Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, et
al: Identification of nesfatin-1 as a satiety molecule in the
hypothalamus. Nature. 443:709–712. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cowley MA and Grove KL: To be or NUCB2, is
nesfatin the answer? Cell Metab. 4:421–422. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y
and Xu Y: Prognostication of prostate cancer based on NUCB2 protein
assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res.
32:772013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cao X, Liu XM and Zhou LH: Recent progress
in research on the distribution and function of NUCB2/nesfatin-1 in
peripheral tissues. Endocr J. 60:1021–1027. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
García-Galiano D, Navarro VM, Gaytan F and
Tena-Sempere M: Expanding roles of NUCB2/nesfatin-1 in
neuroendocrine regulation. J Mol Endocrinol. 45:281–290. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li QC, Wang HY, Chen X, Guan HZ and Jiang
ZY: Fasting plasma levels of nesfatin-1 in patients with type 1 and
type 2 diabetes mellitus and the nutrient-related fluctuation of
nesfatin-1 level in normal humans. Regul Pept. 159:72–77. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong J, Xu H, Xu H, Wang PF, Cai GJ, Song
HF, Wang CC, Dong ZT, Ju YJ and Jiang ZY: Nesfatin-1 stimulates
fatty-acid oxidation by activating AMP-activated protein kinase in
STZ-induced type 2 diabetic mice. PLoS One. 8:e833972013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Su Y, Zhang J, Tang Y, Bi F and Liu JN:
The novel function of nesfatin-1: Anti-hyperglycemia. Biochem
Biophys Res Commun. 391:1039–1042. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gonzalez R, Reingold BK, Gao X, Gaidhu MP,
Tsushima RG and Unniappan S: Nesfatin-1 exerts a direct,
glucose-dependent insulinotropic action on mouse islet β- and MIN6
cells. J Endocrinol. 208:R9–R16. 2011.PubMed/NCBI
|
|
13
|
Suzuki S, Takagi K, Miki Y, Onodera Y,
Akahira J, Ebata A, Ishida T, Watanabe M, Sasano H and Suzuki T:
Nucleobindin 2 in human breast carcinoma as a potent prognostic
factor. Cancer Sci. 103:136–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Qi C, Li L, Luo F and Xu Y:
Clinical significance of NUCB2 mRNA expression in prostate cancer.
J Exp Clin Cancer Res. 32:562013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang H, Qi C, Wang A, Li L and Xu Y: High
expression of nucleobindin 2 mRNA: An independent prognostic factor
for overall survival of patients with prostate cancer. Tumour Biol.
35:2025–2028. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qi C, Ma H, Zhang HT, Gao JD and Xu Y:
Nucleobindin 2 expression is an independent prognostic factor for
clear cell renal cell carcinoma. Histopathology. 66:650–657. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Siegel R, Naishadham D and Jemal A: Cancer
Statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muriel L, ópez C, Esteban E, Berros JP,
Pardo P, Astudillo A, Izquierdo M, Crespo G, Sanmamed M, Fonseca PJ
and Martínez-Camblor P: Prognostic factors in patients with
advanced renal cell carcinoma. Clin Genitourin Cancer. 10:262–270.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen K, Zeng J, Xiao H, Huang C, Hu J, Yao
W, Yu G, Xiao W, Xu H and Ye Z: Regulation of glucose metabolism by
p62/SQSTM1 through HIF1α. J Cell Sci. 129:817–830. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aboudehen K, Kim MS, Mitsche M, Garland K,
Anderson N, Noureddine L, Pontoglio M, Patel V, Xie Y, DeBose-Boyd
R and Igarashi P: Transcription factor hepatocyte nuclear factor-1β
regulates renal cholesterol metabolism. J Am Soc Nephrol.
27:2408–2421. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ramanjaneya M, Tan BK, Rucinski M, Kawan
M, Hu J, Kaur J, Patel VH, Malendowicz LK, Komarowska H, Lehnert H
and Randeva HS: Nesfatin-1 inhibits proliferation and enhances
apoptosis of human adrenocortical H295R cells. J Endocrinol.
226:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dai H, Li X, He T, Wang Y, Wang Z, Wang S,
Xing M, Sun W and Ding H: Decreased plasma nesfatin-1 levels in
patients with acute myocardial infarction. Peptides. 46:167–171.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu Y, Pang X, Dong M, Wen F and Zhang Y:
Nesfatin-1 inhibits ovarian epithelial carcinoma cell proliferation
in vitro. Biochem Biophys Res Commun. 440:467–472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Line A, Stengrēvics A, Slucka Z, Li G,
Jankevics E and Rees RC: Serological identification and expression
analysis of gastric cancer-associated genes. Br J Cancer.
86:1824–1830. 2002. View Article : Google Scholar : PubMed/NCBI
|
